ライフサイエンスコーパス: aldosterone antagonist

1 raction were less likely to be prescribed an aldosterone antagonist.

2 s, or the addition of a thiazide diuretic or aldosterone antagonist.

3 luding ACE inhibitors, beta-blockers, and an aldosterone antagonist.

4 (ACE) inhibitors, beta-blockers, and even an aldosterone antagonist.

5 onverting-enzyme inhibitor, beta blocker, or aldosterone antagonist.

6 angiotensin-converting enzyme inhibitors or aldosterone antagonists.

7 in ischemic events in patients treated with aldosterone antagonists.

8 l suppression with angiotensin II (AT-II) or aldosterone antagonists.

9 in-II modulation 92.8%, beta-blockers 91.5%, aldosterone antagonists 46.3%), and 71.0% had an implant

10 e: beta-blocker (92.2% versus 86.0%, +6.2%), aldosterone antagonist (60.3% versus 34.5%, +25.1%), car

11 yme inhibitor (ACEI), beta-blocker (BB), and aldosterone antagonist (AldA) therapies for patients wit

12 enzyme inhibitors, beta-adrenergic blockers, aldosterone antagonists, and digoxin.

13 ors, angiotensin II receptor antagonists and aldosterone antagonists are bringing new insights not on

14 Aldosterone antagonists are recommended for patients wit

15 antagonist therapy, 4087 (32.5%) received an aldosterone antagonist at discharge, and treatment incre

16 le patients, 1,023 (9.1%) were prescribed an aldosterone antagonist at discharge.

17 In clinical trials, aldosterone antagonists decrease cardiovascular mortalit

18 nic heart failure in more than a decade: the aldosterone antagonist eplerenone in 2003 and a fixed do

19 eta-blockers, angiotensin II inhibitors, and aldosterone antagonists followed by the beta(2)-agonist

20 symptoms, angiotensin-receptor blockers and aldosterone antagonists have additional benefits.

21 bitors, angiotensin II receptor blockers and aldosterone antagonists have all been shown to decrease

22 tensin receptor blockers, beta-blockers, and aldosterone antagonists have improved mortality in patie

23 ngiotensin receptor blockers, beta-blockers, aldosterone antagonists, hydralazine/isosorbide dinitrat

24 otensin II receptor blockers, beta-blockers, aldosterone antagonists, hydralazine/nitrates, statin th

25 locker use, evidence-based beta-blocker use, aldosterone-antagonist, hydralazine/nitrate; p < 0.05) e

26 ngiotensin receptor blockers, beta-blockers, aldosterone antagonists, implantable cardioverter defibr

27 beta-blockers in 20.3% (50.5% of eligible), aldosterone antagonists in 24.1% (87.4% of eligible), hy

28 Prior studies suggest underuse of aldosterone antagonists in eligible patients as well as

29 anism for the vascular protective effects of aldosterone antagonists in humans and support targeting

30 From 2006 to 2009, the use of aldosterone antagonists increased from 6.0% to 13.4% (p

31 Although SPIR is an aldosterone antagonist, its antitumor effects are indepe

32 tment with ACE inhibitors, beta-blockers, an aldosterone antagonist, or their combinations.

33 not COX-2 inhibitors, with corticosteroids, aldosterone antagonists, or anticoagulants produces sign

34 Concomitant use of nsNSAIDs and aldosterone antagonists produced an IRR for UGIB of 11.0

35 angiotensin II type 1 receptor blockers, or aldosterone antagonists promote beneficial renal actions

36 In clinical trials, aldosterone antagonists reduce cardiovascular ischemia a

37 Angiotensin-converting enzyme inhibitors and aldosterone antagonists should also be used in these pat

38 Aldosterone antagonists slow the progression of chronic

39 iPro rats that did versus did not ingest the aldosterone antagonist spironolactone had lower distal n

40 The aldosterone antagonist spironolactone, when used in seve

41 study explored temporal trends in the use of aldosterone antagonist therapy among eligible patients w

42 Use of aldosterone antagonist therapy among patients with docum

43 associated with hyperkalemia was higher with aldosterone antagonist therapy at 30 days (HR, 2.54; 95%

44 as 77.6 years; of those 1070 (18.2%) started aldosterone antagonist therapy at discharge.

45 Initiation of aldosterone antagonist therapy at hospital discharge was

46 Aldosterone antagonist therapy for heart failure and red

47 Limited data exist regarding the impact of aldosterone antagonist therapy on cardiac structure and

48 Current guidelines recommend initiation of aldosterone antagonist therapy post-AMI for patients wit

49 opriate and potentially inappropriate use of aldosterone antagonist therapy was low and did not chang

50 Among 12,565 patients eligible for aldosterone antagonist therapy, 4087 (32.5%) received an

51 09, of whom 11,255 (13.8%) were eligible for aldosterone antagonist therapy.

52 t registry received HF guideline-recommended aldosterone antagonist therapy.

53 erved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) and randomized to spiron

54 atment of Preserved Cardiac Function with an Aldosterone Antagonist (TOPCAT) is an ongoing randomized

55 erved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) patients with heart fail

56 erved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial and related to the

57 erved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial before initiation

58 erved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial of 1372 patients w

59 erved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial who were in sinus

60 erved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

61 erved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

62 erved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT), 3400 patients com

63 s 27%), and higher rates of beta-blocker and aldosterone antagonist use (P<0.0001 for all) than those

64 There was also wide variation in aldosterone antagonist use among hospitals (0%-90.6%).

65 Although rates of aldosterone antagonist use are increasing slightly over

66 Aldosterone antagonist use in eligible patients was asso

67 Aldosterone antagonist use varied from 0% to 40% among h

68 ted with improved 24-month survival, whereas aldosterone antagonist use was not.

69 erved Cardiac Function Heart Failure With an Aldosterone Antagonist) was categorized as poor, interme

70 ndependently associated with prescription of aldosterone antagonists were a history of diabetes, hear

71 bitors or angiotensin receptor blockers, and aldosterone antagonists were prescribed in 18.8%, 10.6%,